COVID-19

Practice Management Systems Market is Projected to Reach US$36.33 billion at CAGR of 9.3% Amid Need for Operational Efficiency & Automation | The Insight Partners

NEW YORK, Sept. 29, 2025 /PRNewswire/ -- A new in-depth report by The Insight Partners highlights Practice Management Systems market growth,...

SeaStar Medical Reports Positive Early Results for QUELIMMUNE Therapy in Pediatric Acute Kidney Injury (AKI) at the 5th International Symposium on Acute Kidney Injury in Children

Data show results consistent with clinical trial experienceA high level of safety – no device-related adverse eventsStrong survival data extending...

OPEN Healthcare Celebrates Grand Opening of 23,000 Sq. Ft. Innovative Diagnostic Laboratory and Launch of At-Home Testing Service in Gardena, California

GARDENA, CALIFORNIA / ACCESS Newswire / September 25, 2025 / OPEN Healthcare proudly announces the grand opening of its new...

AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen® (Rintatolimod) with Checkpoint Inhibitors

Patent supports AIM’s strategy to expand international market protection, providing opportunities for licensing, collaborations, and long-term revenue growth Japan is...

Hemostemix Files FDA Submission for Basket Protocol (Filing 1517) to Advance ACP-01 (VesCell(TM)) Across Multiple Ischemic and Vascular Indications Simultaneously

Calgary, Alberta--(Newsfile Corp. - September 23, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's...

SeaStar Medical to Present Early SAVE Registry Data of QUELIMMUNE in Pediatric Acute Kidney Injury at the 5th International Symposium on Acute Kidney Injury in Children

DENVER, Sept. 23, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company, announced today that...

IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift

Results from OVATION 2 Study reinforce IMNN-001 efficacy benefits observed in the clinic and unique mechanism of action, producing key...

error: Content is protected !!